Business Wire

Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience

Share

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”

Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.

“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

About Eisai Inc.

Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724837236/en/

Contacts

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
Medidata.AR@3ds.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SUI Group Announces Completion of Existing $2 Million Stock Repurchase Program and Subsequent Authorization of New $50 Million Program12.9.2025 23:05:00 EEST | Press release

SUI Group Holdings Limited (“SUI Group,” “SUIG” or the “Company”) (NASDAQ: SUIG), the only publicly traded company with an official relationship with the Sui Foundation, today announced it has completed its previously authorized $2 million stock repurchase program. SUI Group is also announcing that its Board of Directors has now authorized a new stock repurchase program to acquire up to an additional $50 million of the Company’s common stock. Following the completion of its initial stock repurchase program, in which the Company repurchased approximately 318,743 shares of its common stock at an average price of $4.30 per share between September 10, 2025 and September 12, 2025, SUI Group’s new program provides the flexibility to support its Net Asset Value (“NAV”) per share by opportunistically purchasing its common stock. The Company believes that share repurchases at these levels are immediately accretive to existing stockholders and reflects its confidence in its underlying fundamenta

Allied Nations Gather to Discuss Future of Multilateral Defence Security Financing12.9.2025 18:35:00 EEST | Press release

The Defence, Security and Resilience Bank (DSRB) Development Group co-hosted an international conference in the City of London this week to discuss the creation of a new multilateral bank designed to bring capital market expertise to the frontlines of global security. The event at Mansion House, co-hosted by the Lord Mayor of London, included 72 attendees from 37 countries across the NATO alliance, the EU, and Indo-Pacific allied nations. Held on the eve of the Defence and Security Equipment International (DSEI event), the DSRB “Information Day” event also included a further 88 attendees from a wide range of institutions including the European Union, NATO, eight partner commercial banks, multiple development and central banks as well as representatives from global funds, ratings agencies, industry associations and think tanks. Notes to Editors: The DSR Bank Development Group is a non-profit working toward the establishment of the full bank alongside nation states and institutions. The

Illumination and Nintendo Announce the New Animated Film Based on the World of Super Mario Bros. Will Be Titled The Super Mario Galaxy Movie12.9.2025 16:33:00 EEST | Press release

Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that the title of the new animated film based on the world of Super Mario Bros., will be The Super Mario Galaxy Movie. The film will be released worldwide by Universal Pictures beginning April 3, 2026. In addition, the two companies announced that the returning voice actors for the characters will be: Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), and Kamek (Kevin Michael Richardson). The additional characters and voice cast for The Super Mario Galaxy Movie will be announced at a later date. The Super Mario Galaxy Movie will be released on April 3, 2026 in the US and many additional markets globally, and will be released on April 24, 2026 in Japan, with select territories releasing through

TON Strategy Company Announces Initial Share Repurchases Under $250 Million Program, Buying Below Treasury Asset Value Per Share, and Start of Staking12.9.2025 15:30:00 EEST | Press release

TON Strategy Company (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that it has repurchased over 250,000 shares of its common stock under its previously announced $250 million share repurchase program. Further, the Company has started staking operations, as planned, to generate on-chain income by utilizing its treasury holdings. The Company repurchased shares at an average of $8.32 per share; by comparison, the Company’s TAV per share was $12.181 as of September 11, 2025. This week’s share repurchases and the start of staking underscore TON Strategy Company’s financial strength, commitment to shareholder value, and long-term confidence in The Open Network (TON) ecosystem. They coincide with recent milestones in the broader TON network – including the availability of $TON on Gemini, Robinhood, and Zengo – which the Company believes represent steps toward broader market access for the token as the native asset of TON,

Ant Group’s AI Healthcare App AQ Users Reach 140 Million, 60% from Tier-three and Lower-Tier Cities12.9.2025 14:38:00 EEST | Press release

At the 2025 INCLUSION · Conference on the Bund in Shanghai, Ant Group’s AI-powered healthcare app AQ has rolled out a new suite of service updates aimed at making healthcare more inclusive and accessible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250912715926/en/ Ant Group’s AI healthcare app supports users’ daily health needs, extending doctors’ reach beyond time and space. “We hope AI can empower doctors by extending their reach to more patients, freeing up time for medical research and the fight against complex diseases, while equipping community doctors with powerful AI assistants,” said Cyril Han, CEO of Ant Group. Since AQ’s official launch in China in June 2025, following public testing that began in September 2024, the app has served 140 million users, with 60% coming from third-tier cities and below. It offers more than 100 AI-powered services to support users in their daily healthcare needs, including doctor r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye